Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) Equity Average (2016 - 2025)

Historic Equity Average for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $177.6 million.

  • Angiodynamics' Equity Average fell 734.63% to $177.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $177.6 million, marking a year-over-year decrease of 734.63%. This contributed to the annual value of $194.3 million for FY2025, which is 3345.3% down from last year.
  • As of Q4 2025, Angiodynamics' Equity Average stood at $177.6 million, which was down 734.63% from $180.9 million recorded in Q3 2025.
  • Angiodynamics' Equity Average's 5-year high stood at $454.6 million during Q1 2021, with a 5-year trough of $177.6 million in Q4 2025.
  • Its 5-year average for Equity Average is $335.7 million, with a median of $402.9 million in 2023.
  • As far as peak fluctuations go, Angiodynamics' Equity Average surged by 85.54% in 2023, and later tumbled by 5375.92% in 2024.
  • Over the past 5 years, Angiodynamics' Equity Average (Quarter) stood at $434.2 million in 2021, then fell by 5.33% to $411.0 million in 2022, then increased by 0.86% to $414.5 million in 2023, then plummeted by 53.76% to $191.7 million in 2024, then decreased by 7.35% to $177.6 million in 2025.
  • Its last three reported values are $177.6 million in Q4 2025, $180.9 million for Q3 2025, and $184.4 million during Q2 2025.